Retension Pharmaceuticals Inc RTSN

$12.27 +0.02 (0.16%)

Valuation

Market cap
102,229,000
Revenue TTM
$0
Net income TTM
$-6,301,282
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
124,900
Avg volume
—
Day's range
$11.37 – $12.70
Shares out
8,332,000
Stochastic %K
78%
Beta
—
Analysts
Strong Buy
Price target
$51.67

Price

Company profile

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the d...

Show more

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.

Industry
Biotechnology
Sector
Healthcare
Phone
(703) 940-9761
Website
https://www.retensionpharmaceuticals.com
Address
1104 West Broad Street #1029, Falls Church, United States

Latest news

No headlines yet.